News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research> M Stanley Cuts WEIGAO GROUP (01066.HK) TP to HKD5.2, Lowers EPS Forecasts
M Stanley issued a research report stating that it raised revenue forecasts for WEIGAO GROUP (01066.HK) for 2026 to 2028 by 4% each year, reflecting annual growth of about 4% to 5%...
Reset
Send
The window will close in 5 seconds
<Research> M Stanley Cuts WEIGAO GROUP (01066.HK) TP to HKD5.2, Lowers EPS Forecasts
Close
Recommend
5
Positive
3
Negative
3
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

M Stanley issued a research report stating that it raised revenue forecasts for WEIGAO GROUP (01066.HK)  -0.040 (-1.136%)    Short selling $23.46M; Ratio 36.002%   for 2026 to 2028 by 4% each year, reflecting annual growth of about 4% to 5%, at the lower end of managements latest guidance. However, the broker lowered its gross margin assumptions for 2026 to 2030 to reflect ongoing pricing pressure and the impact of volume-based procurement on general consumables, and fine-tuned operating expense ratios in line with trends.

The broker has incorporated WEIGAO GROUPs full-year 2025 results and cut its EPS forecasts for 2026 to 2028 by 14.7%, 13.8% and 14.2%, respectively. Based on an updated RMB to HKD exchange rate of 1.14, it reduced the TP from HKD6 to HKD5.2 and maintained an Equalweight rating.

The broker noted that WEIGAO GROUP has diversified exposure across multiple medical technology segments in China, including general consumables, orthopedics, pharmaceutical packaging, interventional products and blood management. It operates one of the most efficient sales and distribution networks in the industry, providing a strong platform for launching new products. However, recent growth has been affected by price cuts and below-average industry sales volume, alongside ongoing headwinds from DRG and volume-based procurement policies. The Equalweight rating reflects reasonable valuation supported by a stable growth trajectory and dividend yield.


HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25
Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.